Abstract-Several neurotrophic factors (NTF) are shown to be neuroprotective and neurorestorative in pre-clinical animal models for Parkinson's disease (PD), particularly in models where striatal dopamine neuron innervation partially exists. The results of clinical trials on late-stage patients have been modest. Subthalamic deep brain stimulation (STN DBS) is a proven treatment for a selected group of advanced PD patients. The cerebral dopamine neurotrophic factor (CDNF) is a promising therapeutic protein, but its effects in animal models of late-stage PD have remained under-researched. The interactions of NTF and STN DBS treatments have not been studied before. We found that a nigral CDNF protein alone had only a marginal effect on the behavioral deficits in a late-stage hemiparkinsonian rat model (6-OHDA MFB). However, CDNF improved the effect of acute STN DBS on front limb use asymmetry at 2 and 3 weeks after CDNF injection. STN lesion-modeling chronic stimulation-had an additive effect in reducing front limb use in the cylinder test and apomorphine-induced rotation. The combination of CDNF and acute STN DBS had a favorable effect on striatal tyrosine hydroxylase. This study presents a novel additive beneficial effect of NTF and STN DBS, which might be explained by the interaction of DBS-induced endogenous NTFs and exogenously injected CDNF. SNpc can be reached via similar trajectories used in clinical STN DBS, and this interaction is an important area for future studies. Ó 2018 Published by Elsevier Ltd on behalf of IBRO.
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Experimental DBS is often termed high-frequency 31 stimulation (HFS), alluding to the finding that only 32 frequencies higher than about 60 Hz alleviate the motor 33 symptoms produced in the animal models of PD 34 (Fogelson et al., 2005) , and the standard 130-Hz fre-35 quency used produces mainly the inhibition of STN cells 36 (Tai et al., 2003) . In most animal studies, stimulation 37 comes from an external pulse generator that limits the 38 duration of continuous HFS to hours, or at the most, days. nigra (Voutilainen et al., 2011 ) depends on striatal dopa-78 mine innervation (Ma¨tlik et al., 2017) . Additionally, BDNF 79 (Spina et al., 1992) , FGF-2 (Otto and Unsicker, 1990 ) and 80 VEGF (Yasuhara et al., 2004) therapy, but their efficacy has been variable (Kordower 86 et al., 1999; Gill et al., 2003; Lang and Obeso, 2004;  87 Lang et al., 2006; Penn et al., 2006; Patel and Gill, 88 2007; Bartus and Johnson, 2017b group of patients with less-progressed disease (Olanow 92 et al., 2015) . Analysis of the brains of PD patients has 93 shown that there is minimal or no putaminal TH 94 immunoreactive innervation after 5 years post-diagnosis 95 (Kordower et al., 2013) . Therefore, the relatively rapid 96 development of putaminal dopaminergic axonopathy 97 should be taken into account in future trials (Tenenbaum 98 and Humbert-Claude, 2017) , particularly when there are striatum (Airavaara et al., 2012b; Domanskyi et al., 2015) . (Lindholm et al., 2007; Voutilainen et al., 2009; Lindahl 107 et al., 2017) . In a rat 6-OHDA model of PD where 6-
108
OHDA was administered to the striatum, both CDNF 109 and mesencephalic astrocyte-derived neurotrophic factor 110 (MANF) have been shown to be neuroprotective and neu-111 rorestorative (Lindholm et al., 2007; Voutilainen et al., 112 2009 Voutilainen et al., 112 , 2011 Ren et al., 2013; Ba¨ck et al., 2013a (Lindholm et al., 2007) ; (Voutilainen et al., 2009 hoc tests p > 0.9) (Fig. 1D ), but CDNF had no effect on 447 body weight. OHDA would improve the behavioral recovery ( Fig. 2A) . with CDNF (Fig. 4A) . on body weight has been described before for intranigral 680 injections in rats (Hoffer et al., 1994; Martin et al., 1996; 681 Lapchak et al., 1997) and monkeys (Gash et al., 1995) . (Rowland et al., 2016) . advanced PD used in this study (Hudson et al., 1993 Neurorestoration. Parkinsonism Relat Disord 18:S143-S146. 
